Dianthus Therapeutics (Dianthus Therapeutics) GF Value Rank : 0 (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics GF Value Rank?

Dianthus Therapeutics has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Dianthus Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023